In vivo, administration of dimethylaminomicheliolide, a pro-drug of MCL, reduced unilateral ureteric obstruction–induced renal fibrosis that was associated with lesser pEMT and a reduction in IL-11–related pathologies. The gene discussed is IL11; the disease is renal fibrosis.